NeuroPace (NPCE)
(Real Time Quote from BATS)
$7.11 USD
+0.14 (2.01%)
Updated Sep 17, 2024 01:58 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
NeuroPace, Inc. (NPCE) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$14.17 | $18.00 | $8.00 | 103.30% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for NeuroPace, Inc. comes to $14.17. The forecasts range from a low of $8.00 to a high of $18.00. The average price target represents an increase of 103.3% from the last closing price of $6.97.
Analyst Price Targets (6 )
Broker Rating
NeuroPace, Inc. currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by six brokerage firms. The current ABR compares to an ABR of 1.33 a month ago based on six recommendations.
Of the six recommendations deriving the current ABR, five are Strong Buy, representing 83.33% of all recommendations. A month ago, Strong Buy represented 83.33%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.33 | 1.33 | 1.33 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/5/2024 | Lake Street Capital Markets | Frank Takkinen | Strong Buy | Strong Buy |
8/14/2024 | Cantor Fitzgerald & Co | Ross Osborn | Strong Buy | Strong Buy |
8/14/2024 | Wells Fargo Securities | Vikramjeet S Chopra | Strong Buy | Strong Buy |
8/13/2024 | SVB Securities | Michael Kratky | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.33 |
ABR (Last week) | 1.33 |
# of Recs in ABR | 6 |
Average Target Price | $14.17 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 63 of 253 |
Current Quarter EPS Est: | -0.26 |
NPCE FAQs
NeuroPace, Inc. (NPCE) currently has an average brokerage recommendation (ABR) of 1.33 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 6 brokerage firms.
The average price target for NeuroPace, Inc. (NPCE) is $14.17. The current on short-term price targets is based on 4 reports.
The forecasts for NeuroPace, Inc. (NPCE) range from a low of $8 to a high of $18. The average price target represents a increase of $103.30 from the last closing price of $6.97.
The current UPSIDE for NeuroPace, Inc. (NPCE) is 103.30%
Based on short-term price targets offered by six analysts, the average price target for NeuroPace, Inc. comes to $14.17. The forecasts range from a low of $8.00 to a high of $18.00. The average price target represents an increase of 103.3% from the last closing price of $6.97.